Original Article | Published:

A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility

Genes and Immunity volume 15, pages 126132 (2014) | Download Citation

Abstract

Genome-wide association studies (GWASs) perform per-SNP association tests to identify variants involved in disease or trait susceptibility. However, such an approach is not powerful enough to unravel genes that are not individually contributing to the disease/trait, but that may have a role in interaction with other genes as a group. Pathway analysis is an alternative way to highlight such group of genes. Using SNP association P-values from eight multiple sclerosis (MS) GWAS data sets, we performed a candidate pathway analysis for MS susceptibility by considering genes interacting in the cell adhesion molecule (CAMs) biological pathway using Cytoscape software. This network is a strong candidate, as it is involved in the crossing of the blood–brain barrier by the T cells, an early event in MS pathophysiology, and is used as an efficient therapeutic target. We drew up a list of 76 genes belonging to the CAM network. We highlighted 64 networks enriched with CAM genes with low P-values. Filtering by a percentage of CAM genes up to 50% and rejecting enriched signals mainly driven by transcription factors, we highlighted five networks associated with MS susceptibility. One of them, constituted of ITGAL, ICAM1 and ICAM3 genes, could be of interest to develop novel therapeutic targets.

Introduction

Multiple sclerosis (MS) is a common inflammatory and demyelinating disease of the central nervous system.1 Epidemiological studies have proved the multifactorial causes of the disease, resulting from the interaction between genetic factors and currently unknown environmental factors.2

To date, MHC genetic variants, as well as 110 non-MHC variants, have been associated with MS susceptibility by genome-wide association studies (GWASs).3, 4, 5, 6, 7 However, it has been estimated that several other genes contribute to disease susceptibility and are yet to be identified.8

Several hypotheses have been proposed to explain the missing heritability.9, 10 One of them points to the interactions between genes involved in the same biological pathway.11, 12 According to this hypothesis, some of the genes implicated in MS susceptibility cannot on their own reach GWAS significance but when grouped in a pathway may collectively contribute to the MS genetic component.

The initial event leading to the development of an MS lesion is blood–brain-barrier (BBB) disruption and the crossing of the latter by peripherally activated T cells.13 This step, which is a key mechanism in our current understanding of MS physiopathology, requires the interaction of integrins, cell surface molecules expressed by T cells, with the adhesion molecules expressed by the BBB endothelium, ultimately allowing the lymphocytes transmigration into the brain.14, 15, 16, 17

The importance of the BBB crossing in MS physiopathology is stressed by the use of treatments active on adhesion molecules. For example, Natalizumab, a monoclonal antibody blocking the interaction between VLA-4 (very late antigen-4) molecule (composed of ITGB1, integrin beta 1 and integrin alpha 4 (ITGA4), integrin subunits) and its receptor VCAM1 (vascular cell adhesion molecule-1), is among the most efficient therapies available for MS patients thus far.18, 19 The role of adhesion molecules in MS has also been reinforced by the demonstration that the expression of ALCAM (activated leukocyte cell adhesion molecule) located at the surface of the BBB endothelium was increased during the inflammatory process in MS patients. In the same study, it has been shown that in vitro expression of ALCAM, ICAM1 (intercellular cell adhesion molecule-1) and VCAM1 was dependent on activation of the human BBB endothelial cells by pro-inflammatory cytokines (tumor necrosis factor (TNF) and interferon-gamma (IFN-γ)).20

Moreover, genetic studies pointed out the importance of adhesion molecules in the susceptibility to the disease.21, 22 In 2003, we reported that a rare haplotype of the ICAM1 gene (intercellular adhesion molecule-1, expressed at the surface of endothelial cells) was under-transmitted to patients, suggesting a protective effect of this haplotype.21 In 2009, a pathway meta-analysis combining two GWASs uncovered genetic variants that interacted in the cell adhesion molecule (CAM) pathway potentially contributing to MS development.22 This new strategy led to the identification of new genes that do not significantly contribute to MS susceptibility individually, but have an important role in interaction with other genes of the biological pathway. An earlier protein interaction network (PIN)-based pathway analysis considered all the SNPs with a P-value <0.05, without any prior analysis on gene function. That study showed significant interactions among adhesion-molecule-coding genes including ICAM1, ITGB2 (integrin beta 2), ITGAM (integrin alpha M), ITGA6 (integrin alpha 6), CD58 (CD58 molecule), CD2 (CD2 molecule) and CD4 (CD4 molecule). This observation, coming from a meta-analysis of two independent GWAS, suggests that the biological network of adhesion molecules is involved in MS susceptibility.

In order to decipher the role of the CAM pathway in MS susceptibility, we conducted a candidate pathway analysis focusing on adhesion molecules. We found five networks of the CAM pathway enriched in low P-values for genes interacting synergistically to confer MS susceptibility.

Results

CAM pathway-selected genes

Using KEGG database and the Sabiosciences website, we identified 76 genes of interest involved in the adhesion molecule pathway. More than 85% of them (66 out of 76) were involved in three subpathways: adhesion, adherens junctions and tight junctions, and 10 of them encode for transcription factors highly involved in adhesion molecule genes regulation (Supplementary Table 1).

Using data from eight GWAS studies, we selected calculated P-values of identified CAM genes (±1 kb from the 5′ and 3′ UTR). Seven GWASs (IMSGC UK, IMSGC US, ANZGene, GeneMSA DU, GeneMSA SW, GeneMSA US and BWH/MIGEN) constituted the D1 data set.4 The 8th GWAS Wellcome Trust Case Control Consortium 2 (WTCCC2) constituted the D2 data set3 (Figure 1).

Figure 1
Figure 1

D1 and D2 P-value computation. The colored circle represents SNPs. The number of SNPs varies for the different genes (from 1 to 539 in the different data sets, Supplementary Table 2). Data from each GWAS are composed of P-values assigned to each SNP localized within 70 CAM genes (gene boundaries ±1 kb). Data set-A: GWAS ANZGene; Data set-B: GWAS BWH/MIGEN; Data set-C: GWAS MSA DU; Data set-D: GWAS MSA SW; Data set-E: GWAS MSA US; Data set-F: GWAS IMSGC US; Data set-G: GWAS IMSGC UK; and Data set-H: GWAS WTCCC2. VEGAS Software computes one gene-wise P-value to each gene and GWAS Fischer product computes D1 P-value to each gene.

A total of 70 out of the 76 genes were represented by at least one SNP in at least one of the seven data sets included in D1, whereas 68 out of the 76 genes were represented by at least one SNP in the WTCCC2 data set (D2 data set). Six out of the 76 genes of interest were thus excluded from further analysis. The number of available SNPs per gene and per data set is given in Supplementary Table 2. D1 and D2 gene-wise P-values computed using VEGAS software and Fisher test for D1 (Materials and methods section and Figure 1) are given in Table 1. As expected, CD58 (PD1=1.89 × 10−6, PD2=0 (meaning that P<89 × 10−6, Materials and methods section)), NFKB1 (PD1=0.0125, PD2=0.0011) and STAT3 (PD1=2.94 × 10−5, PD2=1.5 × 10−5) genes that were previously identified as associated with MS in GWAS show low gene-wise P-values.

Table 1: D1_ and D2_Gene-wise P-values

Interestingly, VCAM1, previously identified as associated with the disease, with rs11581062 being the most statistically significant SNP, did not reach a significant P-value (PD1=0.7224; PD2=0.993) either in the D1 or in the D2 data sets. The published associated SNP (rs11581062) is 202 kb far from the VCAM1 gene. We conclude that even if VCAM1 is a good candidate gene for MS physiopathology, not enough evidence support its involvement within the rs11581062 region. Furthermore, no CIS-e-QTL regulating VCAM1 expression was described within the 1-Mb region around the gene (Pritchard lab resources).

Subnetworks associated with MS susceptibility

As described by IMSGC,23 we used a curated human PIN data set, which consisted in a network of more than 400 000 interactions among 25 000 proteins. In order to be confident with the interactions, we selected those quoted in at least two publications, and as a result we obtained a reduced human PIN data set of 8920 proteins and 27 724 interactions. Using Cytoscape software, we attributed gene-wise P-values to 70 of the 76 CAM genes (listed in Supplementary Table 1). As mentioned in IMSGC,23 Cytoscape plugin jActives modules was used to calculate a global score (Z-score) for all the possible networks that could be generated from the PIN data set, using D1 and D2 P-values. Networks with Z-scores >3.0 are generally considered significant, that is, these subnetworks are enriched in CAM genes showing D1 and/or D2 gene-wise significant P-values. The cytoscape software was applied on the reduced human PIN data set, containing CAM genes (Supplementary Table 1 and Figure 2) and non-CAM ones. Sixty-four networks were highlighted regarding the enrichment of CAM genes with significant P-values. Focusing on the process of BBB transmigration by T cells, we only considered six networks as relevant for our study, with at least 50% of CAM genes. Finally, we excluded networks that were only enriched in CAM transcription factors to prevent from non-specific association signals only driven by transcription factors (Table 2 and Figure 2). We identified five networks constituted by genes known to interact together within the CAM pathway and meeting all expressed criteria (Figure 3).

Figure 2
Figure 2

Steps of the protein interaction network-based pathway analysis.

Table 2: Selection criteria of the sub-networks
Figure 3
Figure 3

Networks enriched in CAM genes with significant D1 and/or D2 P-value. Each node represents a gene product at each edge; a physical interaction has been reported in at least two independent publications. Each network is enriched with CAM genes having low P-values. Nodes are colored according to D1 P-values (red: highly significant, orange: moderate, yellow and white: not significant). Analysis was performed using Cytoscape and jActive module plugin.

Discussion

GWAS and replication studies have successfully identified approximately 110 non-MHC MS susceptibility genes.3, 4, 5, 6, 7 However, an important part of genetic heritability remains to be discovered.3 One of the hypotheses that can be put forward postulates that genes without individual effect could influence the susceptibility to the disease through genetic interactions.11 Here, we report the first candidate pathway analysis on the CAM network in MS. Our results highlight five networks enriched in CAM genes with significant P-values, reflecting a potential genetic contribution of these molecules in MS susceptibility.

In 2009, Baranzini et al.22 identified seven genes of the CAM pathway as associated with MS susceptibility considering their interaction. Focusing on the CAM pathway and using two powerful datasets (5545+9772 patients and 12 153+17 376 controls), our study refines the role of these genes as MS genetic factors.

Two out of the five identified networks (network 2 and 27) appear to be the highest contributors to MS physiopathology. Network 2 is constituted by ICAM1, ICAM3 and ITGAL genes that are involved in the adhesion process of the T cells on the endothelial cells of the BBB. The adhesion process between endothelial and T cells is one of the earliest events in MS development leading to T-cell transmigration into the central nervous system across the BBB. Of note, ITGAL, ICAM1 and ICAM3 molecules constitute ligand–receptor complexes, ITGAL interacting both with ICAM1 and with ICAM3. Our hypothesis on the role of these genes in MS susceptibility is that some intra- and inter-gene combinations of polymorphisms could influence the adhesion process of T cells on the BBB, leading to a positive or negative modulation of the inflammatory cells’ flow into the central nervous system.

Network 27 is constituted by CD82 (KAI1), ITGA4, ITGB1, ITGB2 and HLA-DMA genes. The ITGB1 and ITGA4 genes code for the two subunits of the very late antigen-4 molecule. CD82 is notably known for its inhibitory effect on ITGB1 activation.24 The effective role of CD82 in inflammatory response has not been yet investigated. In the MS context, it would be relevant to analyze the development and the severity of experimental autoimmune encephalomyelitis (MS animal model) in CD82-deficient mice. As CD82 initiates the differentiation of oligodendrocyte precursors into mature myelinating cells,25 quantification of remyelination in this model would be of interest.

Interestingly, we identified two networks containing the ITGA4 molecule, which is the target of Natalizumab. The interaction between VLA-4 and its receptor VCAM1 is known to be crucial for the transmigration of T cells across the BBB, and our results may potentially underline the genetic basis for this treatment’s effectiveness.

In conclusion, our results highlighting the role of CAM genes’ interactions in MS susceptibility could be of high interest to identify new targets for efficient treatments for MS. A monoclonal antibody directed against ITGA4 that prevents its interaction with VCAM1 already exists.18 We propose that targeting ITGAL or ICAM1 or ICAM3 in order to block their interactions could also be an efficient way to prevent the crossing of the BBB by T cells.

Materials and methods

Ethics statement

All the data used in this study have been generated by previous studies.3, 4 Ethics approval could be found in the corresponding publications.

Selection of genes coding for CAM pathway molecules

Selection of the genes belonging to the network was performed in three phases: using KEGG (Kyoto Encyclopedia for Genes and Genomes) database (http://www.genome.jp/kegg/)26, 27 we searched for adhesion molecules involved in tight and adherens junctions between BBB endothelial cells, and for those involved in T-cell transmigration. Using KEGG database we then identified molecules interacting directly with adhesion molecules. In a last step, we selected the 10 transcription factors that are most involved in adhesion molecule-coding gene expression and regulation using the SabioSciences website (http://www.sabiosciences.com) through GeneCards database (http://www.genecards.org/).28 Using this three-step strategy, we compiled a list of 76 genes of interest.

Data sets

Eight data sets were used in this study. Seven data sets (IMSGC UK, IMSGC US, ANZGene, GeneMSA DU, GeneMSA SW, GeneMSA US and BWH/MIGEN) are described in Patsopoulos et al.4 and constitute the D1 data set. The 8th data set consists in the MS GWAS published by the IMSGC3 and WTCCC2 in 2011 and constitutes the D2 data set. As the IMSGC-WTCCC2 data set is to date the most powerful GWAS published in MS, we decided to use this data set separately to avoid signal losses.

Statistical analysis

Gene-wise P-value computation

With data from eight GWASs, we computed an individual gene-wise P-value corresponding to the association of each gene with MS in each GWAS using VEGAS software29 (Figure 1). VEGAS assigns SNPs to each of 17 787 autosomal genes according to positions on the UCSC Genome Browser (hg18 assembly). For the capture of regulatory regions and SNPs in LD, gene boundaries are defined as ±50 kb of each gene. VEGAS takes into account LD patterns between markers within a gene by using Monte–Carlo simulations from the multivariate normal distribution on the basis of the LD structure of a set of reference individuals (the HapMap2 CEU (Utah residents with ancestry from northern and western Europe from the CEPH collection) population). In VEGAS, the number of simulations per gene is determined adaptively. In the first stage, 103 simulations are performed. If the resulting empirical P-value is <0.1, 104 simulations are then performed. If the empirical P-value from 104 simulations is <0.001, the program will perform 106 simulations. At each stage, the simulations are mutually exclusive. For computational reasons, if the empirical P-value is 0 then no more simulations will be performed. An empirical P-value of 0 from 106 simulations can be interpreted as P<10−6, which exceeds a Bonferroni-corrected threshold of P<2.8 × 10−6.

To combine the gene-wise P-values across the seven data sets described above (named D1), we applied Fisher’s method for each of the 70 selected genes. The gene-wise P-values from the WTCCC2 data set were used separately as a second independent data set (named D2) (Figure 1).

PIN-based pathway analysis

As described by IMSGC23 in 2013, we integrated data from a curated human PIN data set in Cytoscape software.30 Cytoscape plugin jActives modules was used to calculate a global score for each network enriched in CAM genes, showing D1 and/or D2 gene-wise significant P-values. Using successive filters, we identified networks enriched in low P-Values with at least 50% of CAMs genes and less than 50% of transcription factors (Figure 2).

References

  1. 1.

    , . Multiple sclerosis. J Clin Invest 2012; 122: 1180–1188.

  2. 2.

    , . Multiple sclerosis. Lancet 2008; 372: 1502–1517.

  3. 3.

    WTCCC2IMSGC, , , et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

  4. 4.

    , , , , , et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011; 70: 897–912.

  5. 5.

    , , , , , et al. Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet 2013; 50: 140–143.

  6. 6.

    , , , , , et al. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 2013; 136 (Pt 6): 1778–1782.

  7. 7.

    International Multiple Sclerosis Genetics C , , , , et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353–1360.

  8. 8.

    , , , , , et al. Evidence for polygenic susceptibility to multiple sclerosis—the shape of things to come. Am J Hum Genet 2010; 86: 621–625.

  9. 9.

    , , , , , et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747–753.

  10. 10.

    . Elements of 'missing heritability'. Curr Opin Cardiol 2012; 27: 197–201.

  11. 11.

    , , . Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010; 11: 843–854.

  12. 12.

    , , , . Pathway analysis of genomic data: concepts, methods, and prospects for future development. Trends Genet 2012; 28: 323–332.

  13. 13.

    , , . The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta 2011; 1812: 220–230.

  14. 14.

    , . Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol 2004; 34: 2955–2963.

  15. 15.

    , . The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26: 485–495.

  16. 16.

    . Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 2008; 274: 23–26.

  17. 17.

    , , . Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 2007; 17: 243–250.

  18. 18.

    , , , , , . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–66.

  19. 19.

    , , , , , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

  20. 20.

    , , , , , et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008; 9: 137–145.

  21. 21.

    , , , , , et al. Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis. Genes Immun 2003; 4: 518–523.

  22. 22.

    , , , , , et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 2009; 18: 2078–2090.

  23. 23.

    IMSGC. Network-based multiple sclerosis pathway analysis with GWAS data from 15 000 cases and 30 000 controls. Am J Hum Genet 2013; 92: 854–865.

  24. 24.

    , , , , , . Metastasis suppressor KAI1/CD82 attenuates the matrix adhesion of human prostate cancer cells by suppressing fibronectin expression and beta1 integrin activation. Cell Physiol Biochem 2011; 27: 575–586.

  25. 25.

    , . CD82 blocks cMet activation and overcomes hepatocyte growth factor effects on oligodendrocyte precursor differentiation. J Neurosci 2013; 33: 7952–7960.

  26. 26.

    , . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27–30.

  27. 27.

    , , , , . KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012; 40 (Database issue): D109–D114.

  28. 28.

    , , , . GeneCards: integrating information about genes, proteins and diseases. Trends Genet 1997; 13: 163.

  29. 29.

    , , , , , et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet 2010; 87: 139–145.

  30. 30.

    , , , , , et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007; 2: 2366–2382.

Download references

Acknowledgements

This study was supported by the Institut National de la Santé et de la Recherche Médicale, the Fondation pour la Recherche sur la Sclérose En Plaques (ARSEP), the Association Française contre les Myopathies, GIS-IBISA and ICM Carnot Institute. The research leading to these results has received funding from the program ‘Investissements d’avenir’ ANR-10-IAIHU-06. We thank ICM, CIC Pitié-Salpêtrière, Généthon, BRC-REFGENSEP’s and IMSGC’s members for their help and support as well as Jorge Oksenberg and Pierre-Antoine Gourraud. VD received a travel grant from the Fondation ARSEP and ICM Carnot Institute. Philip L De Jager is a Harry Weaver Neuroscience Scholar of the National MS Society. SEB is a Harry Weaver Neuroscience fellow from the US National MS Society. This investigation was supported (in part) by a Postdoctoral Fellowship from the National Multiple Sclerosis Society to Nikolaos A Patsopoulos (FG 1938-A-1).

Author information

Author notes

    • I Cournu-Rebeix
    •  & B Fontaine

    These authors contributed equally to this work.

Affiliations

  1. UPMC-INSERM-UMR_S 1127-CNRS UMR7225, Paris, France

    • V Damotte
    • , L Guillot-Noel
    • , M El Behi
    • , I Cournu-Rebeix
    •  & B Fontaine
  2. Departments of Neurology and Psychiatry, Institute for the Neurosciences, Brigham & Women's Hospital, Boston, MA, USA

    • N A Patsopoulos
    •  & P L De Jager
  3. Division of Genetics, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

    • N A Patsopoulos
  4. Harvard Medical School, Boston, MA, USA

    • N A Patsopoulos
    •  & P L De Jager
  5. Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA

    • N A Patsopoulos
    •  & P L De Jager
  6. Department of Neurology, University of California at San Francisco, Sandler Neurosciences Center, San Francisco, CA, USA

    • L Madireddy
    •  & S E Baranzini
  7. Institut du Cerveau et de la Moelle épinière-ICM, Paris, France

    • M El Behi
  8. Assistance Publique-Hôpitaux de Paris (AP-HP), Département des Maladies du Systéme Nerveux, Hôpital Pitié-Salpêtrière, Paris, France

    • I Cournu-Rebeix
    •  & B Fontaine
  9. Members of the International Multiple Sclerosis Genetics Consortium (IMSGC) are listed at the end of the article.

  10. Members of the Wellcome Trust Case Control Consortium 2 (WTCCC2) are listed at the end of the article.

Consortia

  1. International Multiple Sclerosis Genetics Consortium

    Maria Ban, Sergio Baranzini, Lisa Barcellos, Gary Beecham, Ashley Beecham, Luisa Bernardinelli, David Booth, Steffan Bos, Dorothea Buck, William Bush, Manuel Comabella, Alastair Compston, Chris Cotsapas, Isabelle Cournu-Rebeix, Bruce Cree, Sandra D'Alfonso, Mark Daly, Vincent Damotte, Mary Davis, Paul de Bakker, Philip L De Jager, Benedicte Dubois, Federica Esposito, Bertrand Fontaine, An Goris, Pierre-Antoine Gourraud, Todd Green, Elisabeth Gulowsen Celius, Athena Hadjixenofontos, David Hafler, Jonathan Haines, Hanne F Harbo, Stephen Hauser, Clive Hawkins, Bernhard Hemmer, Jan Hillert, Rogier Hintzen, Dana Horáková, Adrian J Ivinson, Anu Kemppinen, Jun-ichi Kira, Ingrid Kockum, Robin Lincoln, Roland Martin, Filippo Martinelli Boneschi, Jacob L McCauley, Inger-Lise Mero, Jorge Oksenberg, Tomas Olsson, Annette Oturai, Aarno Palotie, Nikolaos Patsopoulos, Margaret Pericak-Vance, John Rioux, Janna Saarela, Stephen Sawcer, Nathalie Schnetz-Boutaud, Finn Sellebjerg, Helle Soendergaard, Per Soelberg Sorensen, Anne Spurkland, Jim Stankovich, Graeme Stewart, Bruce Taylor, Anna Ticca, Sandra West and Frauke Zipp.

  2. Wellcome Trust Case Control Consortium 2

    Management Committee: Peter Donnelly (Chair), Ines Barroso (Deputy Chair), Jenefer M. Blackwell, Elvira Bramon, Matthew A Brown, Juan P Casas, Aiden Corvin, Janusz Jankowski, Hugh S Markus, Christopher G Mathew, Colin NA Palmer, Robert Plomin, Anna Rautanen, Stephen Sawcer, Richard C Trembath, Ananth C Viswanathan and Nicholas W Wood. Data and Analysis Group: Chris CA Spencer, Gavin Band, Céline Bellenguez, Colin Freeman, Garrett Hellenthal, Eleni Giannoulatou, Matti Pirinen, Richard Pearson, Amy Strange, Zhan Su, Damjan Vukcevic and Peter Donnelly. DNA, Genotyping, Data QC and Informatics Group: Cordelia Langford, Sarah E Hunt, Sarah Edkins, Rhian Gwilliam, Hannah Blackburn, Suzannah J Bumpstead, Serge Dronov, Matthew Gillman, Emma Gray, Naomi Hammond, Alagurevathi Jayakumar, Owen T McCann, Jennifer Liddle, Simon C Potter, Rathi Ravindrarajah, Michelle Ricketts, Matthew J Waller, Paul Weston, Sara Widaa, Pamela Whittaker, Ines Barroso and Panos Deloukas. Associate Members: Alexander Dilthey, Stephen Leslie, Loukas Moutsianas, Marc L Perez and Gil McVean. Publications Committee: Christopher G Mathew, Jenefer M Blackwell, Matthew A Brown, Aiden Corvin, Mark I McCarthy and Chris CA Spencer.

Authors

  1. Search for V Damotte in:

  2. Search for L Guillot-Noel in:

  3. Search for N A Patsopoulos in:

  4. Search for L Madireddy in:

  5. Search for M El Behi in:

  6. Search for P L De Jager in:

  7. Search for S E Baranzini in:

  8. Search for I Cournu-Rebeix in:

  9. Search for B Fontaine in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to B Fontaine.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/gene.2013.70

Supplementary Information accompanies this paper on Genes and Immunity website (http://www.nature.com/gene)

Further reading